We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Based on this evidence, First Check determines that this viral video deceptively combines footage to falsely imply COVID ...

The support is designed to speed development of well-matched H5N1 vaccines and pave the way for vaccines against other ...

Yesterday the World Health Organization (WHO) said Tanzania has 1 confirmed case of Marburg and 25 suspected cases all from ...

The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to ...

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.

Whilst vaccines exist for animals, none are commercially available for human use for the mosquito-borne virus.

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...